Evolocumab
IMPACT-SIRIO 5
Phase 3 small_molecule completed
Quick answer
Evolocumab for Sars-CoV-2 Infection is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- COLLEGIUM PHARMACEUTICAL, INC
- Indication
- Sars-CoV-2 Infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed